Merz Therapeutics announces the appointment of Mark Altmeyer as a Non-Executive Director of the company

Frankfurt am Main, 01.11.2023 – Merz Therapeutics announces the appointment of Mark Altmeyer as a Non-Executive Director of the company

At Arvelle, he played a pivotal role in steering the company’s development until its acquisition by Angelini.Preceding his time at Arvelle, Mark served as President and Chief Commercial Officer at Axovant Sciences, where he was responsible for establishing Axovant’s global commercial capabilities and preparing for the launch of various pipeline products. In the earlier stages of his career, Mark served as President and CEO at Otsuka America Pharmaceuticals, where he led the transformation of the organization into a thriving commercial entity, doubling total revenues from USD 2.5 billion to nearly 5 billion within a span of five years. Mark also held significant roles in commercial and business development at Bristol-Myers Squibb, Cetus Corporation, and Bristol Labs in the United States. He holds an MBA from the Harvard Graduate School of Business and a BA in economics from Middlebury College.

Philip Burchard, CEO of the Merz Group and Chairman of the Merz Holding Board, commented on the appointment, stating, “I am delighted that Mark has accepted our invitation to join the Advisory Board of Merz Therapeutics. His illustrious executive career in the Pharma sector and his extensive experience as an entrepreneur make him a valuable addition.”

Stefan König, CEO of Merz Therapeutics, expressed his pleasure, saying, “We are fortunate to have Mark’s expertise on board as we move forward. His exceptional professional journey in the biotech, pharmaceutical, and healthcare sectors is a tremendous asset. This is a pivotal juncture in our company’s evolution, and Mark’s insights and expertise will be indispensable as we implement our growth strategy. I eagerly anticipate collaborating with him as we embark on our journey to become a leading player in the field of neurology-focused specialty pharma.”

Mark Altmeyer shared his thoughts on the appointment, stating, “I am thrilled to join a company with such a rich history and extensive experience in the realm of movement disorders. Merz Therapeutics boasts enormous growth potential as a fully equipped pharmaceutical enterprise with a proven track record in Research and Development and consistent commercial growth. I am genuinely excited to contribute my expertise to enhance Merz Therapeutics’ substantial potential to deliver better outcomes for more patients.”

About Merz Therapeutics

Merz Therapeutics GmbH is dedicated to improving the lives of patients around the world. With its relentless research, development, and culture of innovation, Merz Therapeutics strives to serve unmet patient needs and realize better outcomes. Merz Therapeutics seeks to address the unique needs of people who suffer from movement disorders, neurological conditions, liver disease, and other health conditions that severely impact patients’ quality of life.

Merz Therapeutics is headquartered in Frankfurt am Main, Germany and is represented in more than 90 countries, with a North America affiliate based in Raleigh, North Carolina. Merz Therapeutics GmbH is part of the Merz Group, a privately held, family-owned company that has dedicated 115 years to developing innovations that serve unmet patient and customer needs.

Please visit www.merztherapeutics.com

About Merz

Merz Group is a global, diversified company with its headquarters in Frankfurt, Germany. Its commitment to innovation, long-term perspective, and focus on profitable growth depict the privately owned company that has been founded 115 years ago. Merz Group focusses on the businesses Merz Aesthetics, Merz Therapeutics, Merz Lifecare, Merz Real Estate and Merz Financial Investments. The company employs 4.337 people in 28 countries worldwide.

To learn more, please visit http://www.merz.com/